
SEC jumps into the FibroGen fiasco with a subpoena, probing cardio data manipulation
AstraZeneca partner FibroGen stunned analysts last April with the news that the safety data around their anemia drug roxadustat had been doctored up to make certain safety issues disappear. And now we know that the SEC has decided to get into the act.
From their 10-K yesterday:
In the fourth quarter of 2021, FibroGen received a subpoena from the SEC requesting documents related to roxadustat’s pooled cardiovascular safety data. We have been fully cooperating with the SEC’s investigation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.